Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma

Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma

Abstract Introduction Although anti‐CD19 chimeric antigen receptor (CAR) T cell therapy was approved as a very effective salvage strategy in relapsed/refractory (R/R) B cell lymphoma, the experience in R/R gastrointestinal (GI) lymphoma is still insufficient. Methods We summarized the efficacy and s...

Full description

Bibliographic Details
Main Authors: Yi Li Jiang, Juan Mu, Rui Cui, Xin Li, Jia Wang, Qing Li, Jingyi Li, Nan Mou, Qi Deng
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Cancer Medicine
Subjects:
B‐cell lymphoma
chimeric antigen receptor (CAR)
gastrointestinal lymphoma
relapsed/refractory
Online Access:https://doi.org/10.1002/cam4.7064

Similar Items

Similar Items